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Background: Lenalidomide (LND) is a potent novel thalidomide analog which demonstrated remarkable clinical
activity in treatment of multiple myeloma disease via a multiple-pathways mechanism. The strong evidences-based
clinical success of LND in patients has led to its recent approval by US-FDA under the trade name of Revlimid®
capsules by Celgene Corporation. Fluorimetry is a convenient technique for pharmaceutical quality control,
however there was a fluorimetric method for determination of LND in its bulk and capsules.
Results: A novel highly sensitive and simple fluorimetric method has been developed and validated for the
determination of lenalidmide (LND) in its bulk and dosage forms (capsules). The method was based on nucleophilic
substitution reaction of LND with fluorescamine (FLC) in aqueous medium to form a highly fluorescent derivative
that was measured at 494 nm after excitation at 381 nm. The factors affecting the reaction were carefully studied
and optimized. The kinetics of the reaction was investigated, and the reaction mechanism was postulated. Under
the optimized conditions, linear relationship with good correlation coefficient (0.9999) was found between the
fluorescence intensity and LND concentration in the range of 25–300 ng/mL. The limits of detection and
quantitation for the method were 2.9 and 8.7 ng/mL, respectively. The precision of the method was satisfactory; the
values of relative standard deviations did not exceed 1.4%. The proposed method was successfully applied to the
determination of LND in its bulk form and pharmaceutical capsules with good accuracy; the recovery values were
97.8–101.4 ± 1.08–2.75%.
Conclusions: The proposed method is selective and involved simple procedures. In conclusion, the method is
practical and valuable for routine application in quality control laboratories for determination of LND.
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Lenalidomide (LND) is a potent novel thalidomide
analog which demonstrated remarkable clinical activity
in treatment of multiple myeloma disease [1-5] via a
multiple-pathways mechanism [6-9]. The strong evidences-
based clinical success of LND in patients has led to its
recent approval by US-FDA under the trade name of
Revlimid® capsules by Celgene Corporation [10]. LND
has an improved side effects profile than its parent* Correspondence: idarwish@ksu.edu.sa
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distribution, and reproduction in any mediumcompound thalidomide [11]. These side effects can be
managed by combination therapy and/or careful dose
adjustment [12]. The therapeutic benefits profile of LND
is anticipated to encourage the development of new
pharmaceutical preparations for LND. As a consequence,
there is an increasing demand for proper analytical tech-
nologies for quality assurance of LND formulations.
Few methods have been reported for the determination
LND in bulk material and in capsules. These methods
included two spectrophotometric methods [13]. The first
method was based on diazo-coupling reaction with N-(1-
napthyl) ethylenediamine dihydrochloride and the secondtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sation product with p-dimethylaminocinnamaldehyde. In
addition, two HPLC methods have reported for analysis
of bulk material of LND and its related impurities [14]
and capsules [15]. These methods were associated with
some major drawbacks such as lack of selectivity, time-
consumption and/or use of expensive instruments.
Fluorimetry is considered one of the most convenient
analytical techniques, because of its inherent simplicity,
high sensitivity, low cost, and wide availability in most
quality control laboratories. No attempt has yet been
made for the fluorimetric determination of LND. The
present study describes, for the first time, the develop-
ment of a novel highly sensitive and simple fluorimetric
method for the determination of LND in its bulk form
and capsules. The method was based on the derivatiza-
tion of LND with fluorescamine (FLC) in aqueous
medium to produce a highly fluorescent product that




Fluorescence measurements were carried out on a RF-
5301 PC spectrofluorimeter (Shimadzu Corporation
Kyoto, Japan) equipped with a 150 W xenon lamp and
1 cm quartz cells. The slit widths of both the excitation
and emission monochromators were set at 1.5 nm. The
calibration and linearity of the instrument were fre-
quently checked with standard quinine sulphate. pH
meter Model 211 a product of HANNA Instruments
Inc. (Smithfield, RI, USA).
Reagents and materials
Lenalidomide (LND), free base (3-(4`-aminoisoindoline-
1`-one)-1-piperidine-2,6-dione) (LC Laboratories®, Woburn,
MA, USA ) was obtained and used as received; its purity
was 100.2 ± 1.25%. Fluorescamine (FLC; Sigma Chemical
Co., St. Louis, USA) was prepared in acetonitrile to con-
tain 0.025% (w/v); the solution could be used for seven
days when kept in the refrigerator. Revlimid
®
capsules
(Celgene Corporation, New Jersy, USA) labeled to con-
tain 5 mg LND per capsule was obtained from the local
market. Double distilled water was obtained through
WSC-85 water purification system (Hamilton Laboratory
Glass Ltd., Kent, USA), and used throughout the work.
All other solvents and materials used throughout this
study were of analytical grade.
Preparation of standard and sample solutions
Lenalidomide standard solution
An accurately weighed amount (25 mg) of LND was
quantitatively transferred into a 25-mL calibrated flask,
dissolved in 20 mL methanol, completed to volume withthe same solvent to obtain a stock solution of 1 mg/mL.
This stock solution was further diluted with water to
obtain a working stock solution containing 0.5 μg/mL.
Capsules sample solution
The contents of 20 Revlimid® capsules (Celgene
Corporation, NJ, USA), labeled to contain 5 mg of LEN
per capsule were evacuated and weighed. An accurately
weighed portion equivalent to 50 mg of LND was trans-
ferred into a 50-mL calibrated flask containing ~ 40 mL
of methanol. The contents of the flask were swirled,
sonicated for 5 min, and then completed to volume with
methanol. The contents were mixed well and filtered
rejecting the first portion of the filtrate. The prepared
solution was diluted quantitatively with distilled water
to obtain a suitable concentration for the analysis.
General recommended procedure
Accurately measured aliquots of LND working stock
solution (0.5 μg/mL) were transferred into separate 10-mL
calibrated flasks to obtain a series of LND standard
solutions covering the working range of 25–300 ng/mL
in the final solution. One milliliter of FLC solution
(0.025% w/v) was added to each flask. The reaction was
allowed to proceed at room temperature (25 ± 2°C) for
10 min, and then completed to volume with water. The
fluorescence intensity of the resulting solutions were
measured at 494 nm after excitation at 381 nm against
a reagent blank prepared in the same manner but using
water instead of the LND working stock solution.
Determination of stoichiometric ratio
The Job’s method of continuous variation [16] was
employed. Master equimolar (1.5×10−5 M) aqueous solu-
tions of LND and FLC were prepared. Series of 10-mL
portions of the master solutions of LND and FLC were
made up comprising different complementary propor-
tions (0:10, 1:9, . . ., 9:1, 10:0, inclusive) in 10-mL cali-
brated flasks and the reactions were allowed to proceed
for 10 min. The solutions were further manipulated and
the fluorescence signals were measured as described
under the general recommended procedure.
Results and discussion
Excitation and emission spectra
Because of the absence of native fluorescence of LND,
its derivatization with fluorogenic reagent was necessary
for its fluorimetric determination. FLC was chosen as a
derivatizing reagent because it forms highly fluorescent
derivatives with primary amines under relatively mild
reaction conditions [17]. It was found that LND reacts
with FLC and forms a highly fluorescent derivative that
exhibited maximum fluorescence intensity (λem) at
494 nm after excitation at wavelength (λex) of 381 nm.
Figure 2 Effect of FLC concentration on its reaction with LND
(75 ng/mL).
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product of LND with FLC are given in Figure 1.
Optimization of reaction variables
Effect of FLC concentration
The study of the reaction between LND and FLC
revealed that the reaction was dependent on the FLC
concentration as the relative fluorescence intensity (RFI)
of the reaction mixture increased steadily as the FLC
concentration increased up to a final concentration of
0.002%, w/v (Figure 2). Beyond this concentration, the
slope of the curve significantly decreased. For more pre-
cise readings, a concentration of 0.025% (w/v) of FLC
reagent solution was used throughout the further
experiments.
Effect of pH
The effect of the pH on the reaction was studied by car-
rying out the reaction in borate buffer solution in the
pH range of 6.5–9.5. The results indicated that the RFI
increased initially as the pH increased and maximum
readings were attained at pH 7.0 ± 0.2 (Figure 3). In pre-
vious studies involving FLC as a fluorofore, the max-
imum readings were obtained at pH around 8.0 [18].
This was possibly due to the predominance of the free
amino group of the investigated substance rather than
its salt form in acidic pH. Consequently, this facilitates
the nucleophilic substitution reaction. In the present
study, such alkaline pH was not necessary because the
LND is already in the form of free base. Furthermore,
at higher pH values, sharp decrease in the readings
occurred (Figure 3). This was probably attributed to
the hydrolysis of the reaction product between LND
and FLC in alkaline medium. Neutral pH was found
to be optimum for the reaction between LND and
FLC. Distilled water was compared with borate buffer
of pH 7, and similar results were obtained. Therefore,Figure 1 Excitation (1) and emission (2) spectra of the reaction
product of LND (275 ng/mL) with FLC (0.025%, w/v).the reactions in all the subsequent experiments were
carried out in distilled water. This was in favor of the
simplicity of the proposed procedure, and environmen-
tal and health safety.Effect of time
In order to determine the optimum time required for
completion of the reaction, the derivatization reaction
was carried out at room temperature (25 ± 2°C) and the
induced fluorescence signals were measured immediately
after the addition of FLC and monitored for 30 min. The
optimum reaction time was considered as the time at
which the highest fluorescence signals with reproducible
results are obtained in a comfortable measurement
region on the FI-time curve (wide plateau). The results
indicated that the reaction was very fast and almost
completed within 5 min (Figure 4). Beyond this time, the
RFI values did not change by time. For comfortableFigure 3 Effect of pH on the reaction of FLC (0.025%, w/v) with
LND (130 ng/mL).
Figure 4 Effect of time on the reaction of FLC (0.025%, w/v)
with LND (130 ng/mL).
Table 1 Optimization of variables affecting the reaction
of LND with FLC
Variable Studied range Optimum condition
FLC conc. (%, w/v) 0.00025 – 0.0045 0.0025
pH 6.5–9.5 7 ± 0.2
Reaction time (min) 2–30 10
Solvent Different a Water
Stability of LND-FLC (min) 10–60 10–60
Excitation wavelength, λex (nm) 220–460 381
Emission wavelength, λem (nm) 420–620 494
a Solvents tested: Water, methanol, ethanol, and acetonitrile.
b The stability of the LND-FLC was studied after dilution of the reaction
solution.
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reactions were carried out for 10 min.
Effect of diluting solvent
In order to select the most suitable diluting solvents for
the formation and stability of the reaction product, dif-
ferent solvent were investigated. These solvents were:
water, methanol, ethanol, and acetonitrile. The highest
fluorescence intensities were obtained when water was
used as a diluting solvent (Figure 5).
Stability of the fluorescent derivative
The effect of time on the stability of the LND-FLC fluor-
escent derivative was studied by monitoring the fluores-
cence intensities of the reaction solution (after dilution)
at different time intervals. It was found that the RFI
values remain constant for at least 1 hour. This
allowed the processing of large batches of samples, and
their comfortable measurements with convenience. ThisFigure 5 Effect of diluting solvent on the reaction between
LND (130 ng/mL) and FLC (0.025%, w/v). Solvents were: water,
methanol (MeOH), ethanol (EtOH), and acetonitrile (MeCN).increased the convenience of the method as well as
made it applicable for large number of samples in qual-
ity control laboratories.
A summary for the optimization of the variables
affecting the reaction of LND with FLC is given in
Table 1.Stoichiometry, kinetics and mechanism of the reaction
Under the optimum conditions (Table 1), the stoichiom-
etry of the reaction between LND and FLC was investi-
gated by Job’s method [16]. The symmetrical bell-shape
of Job’s plot (Figure 6) indicated that the LND:FLC ratio
was 1:1. Based on this ratio, the reaction pathway was
postulated to be proceeded as shown in Figure 7.
Under the optimum conditions (Table 1), the RFI-time
curves for the reaction at varying LND concentrations
(1.93×10–7 – 1.16×10–6 M)] with a fixed concentration
of FLC [9×10–5 M)] were generated (Figure 8). The ini-
tial reaction rates (K) were determined from the slopes
of these curves. The logarithms of the reaction rates
(Log K) were plotted as a function of logarithms of LND





















( ex = 381 nm; em = 494 nm)
Figure 7 Scheme for the reaction pathway between LND and
FLC.
Figure 9 Linear plot for Log C versus Log K for the kinetic
reaction of LND and FLC.
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following equation:
Log K ¼ log K0 þ nlogC
where K is reaction rate, K0 is the rate constant, C is the
molar concentration of LND, and n (slope of the regres-
sion line) is the order of the reaction. As seen in Figure 9,
a straight line with slope values of 0.9946 (≈ 1) confirm-
ing that the reaction was first order. However under the
optimized reaction conditions, the concentration of FLCFigure 8 Relative fluorescence intensity (RFI)-time curves for
the reaction of a fixed concentration of FLC with varying
concentrations of LND. LND concentrations were 45 (▽), 95 (♦),
130 (○), 185 (▲), and 260 (□) ng/mL.was in much more excess than that of LND in the reac-
tion solution. Therefore, the reaction was regarded as a
pseudo-first order reaction.Validation of the method
Calibration and sensitivity
Under the optimum conditions (Table 1), calibration
curve for the determination of LND by its reaction with
FLC was constructed by plotting the RFI as a function of
the corresponding LND concentration. The regression
equation for the results was: RFI = a + bC, where RFI is
the relative fluorescence intensity, C is the concentration
of LND in ng/mL. Linear relationship with small inter-
cept and excellent correlation coefficient (r = 0.9999)
was obtained in the range of 25–300 ng/mL. The limit
of detection (LOD) and limit of quantification (LOQ)
were determined according to ICH guidelines for valid-
ation of analytical procedures [19]. The LOD and LOQ
values were found to be 2.9 and 8.7 ng/mL, respectively.
The parameters for the analytical performance of
the proposed fluorimetric method are summarized in
Table 2.Table 2 Statistical parameters for the determination of
LND by the proposed fluorimetric method based on its
reaction with FLC
Parameter Value
Linear range (ng/mL) 25–300
Intercept 11.8
SD of intercept 0.921
Slope 1.047
SD of slope 0.0054
Correlation coefficient (r) 0.9999
LOD (ng/mL) 2.9
LOQ (ng/mL) 8.7
Table 3 Recovery studies for determination of LND by the
proposed fluorimetric method based on its reaction with
FLC
Taken (ng/mL) Recovery (% ± SD)a
100 98.5 ± 2.54
150 97.8 ± 2.02
200 100.1 ± 1.24
250 99.5 ± 2.75
300 101.4 ± 1.08
Average 99.46 ± 1.40
a Values are mean of three determinations.
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The accuracy and precision of the proposed fluorimetric
method was determined by replicate analysis of five
different concentrations of the working standard. The
recovery values were 97.8-101.4 ± 1.08 - 2.75% (Table 3),
indicating the accuracy of the proposed method. The
average recovery from all the concentrations was found
to be 99.5% with SD of 1.40% indicating the good accur-
acy and reproducibility of the results. Furthermore intra-
and inter-day precisions for determination of LND in
bulk powder were assessed at three varying LND con-
centrations (low, medium, and high). The average recov-
ery values were 101.40 and 102.27% with RSD values of
1.13 and 2.29% for intra- and inter-assay precision,
respectively (Table 4). These good recovery values and
low RSD values revealed the high accuracy and preci-
sions, respectively.
Robustness and ruggedness
Robustness was examined by evaluating the influence of
small variation in the method variables on its analytical
performance. In these experiments, one parameter was
changed whereas the others were kept unchanged, and
the recovery percentage was calculated each time. It was
found that variation in the FLC concentrations (0.02–
0.03%, w/v), temperature (optimum ± 2°C), pH (6.8 -
7.2) and time (optimum ± 5 min) did not significantly
affect the recovery values. The most critical factor affect-






Measured conc. (ng/mL) Recovery (% ± RSD
25 25.60 102.40 ± 2.86
100 100.56 100.56 ± 0.67
300 310.50 100.35 ± 0.68
Average 101.10 ± 1.13
a Values are mean of five determinations.
b Values are mean of four determinations.it had to be added accurately to attain a fixed concentra-
tion in all the solutions. Ruggedness was also tested by
applying the method to the assay of LND using fixed
operational conditions within ± 10% changes and on
different days. The results were reproducible and the
RSD% did not exceed 2.29%.Practical applications of the proposed method
It is evident from the above-mentioned results that the
proposed method gave satisfactory results with LND in
bulk form. Also the pharmaceutical dosage forms
(Revlimid® capsules) were analyzed for their LND con-
tent by the proposed method. The percentage found
from the label claim was 100.11 ± 1.61% of the label
claim, indicating the successful applicability of the pro-
posed method in quality control laboratories for deter-
mination of LND. The results obtained by the proposed
method was compared with those obtained by a reported
method [15] with respect to the accuracy (by t-test), and
precision (by F-test). It was found that the calculated
t- and F-values were lower than the tabulated ones. This
indicated that there were no significant differences
between the means and variance between the two
methods in terms of the accuracy and precision.Advantages of the proposed method over the reported
methods
This study represents the first report describing the suc-
cessful evaluation of FLC as an analytical reagent in the
development of a highly sensitive and simple fluori-
metric method for the quantitative determination of
LND. The proposed method is superior to the previously
reported spectrophotometric methods in terms of the
sensitivity and simplicity of the derivatization proce-
dures. As well, the proposed procedure used water as a
green, inexpensive, and safe solvent, rather than the cos-
tive and toxic organic solvents that have been employed
in the previously reported HPLC methods. In addition,
the method employed a simple inexpensive fluorimeter
that is available in most quality control laboratories,
rather than the expensive HPLC systems.r determination of LND by the proposed fluorimetric
Inter-assay
) a Measured conc. (ng/mL) Recovery (% ± RSD) b
26.10 104.44 ± 0.69
102.50 102.50 ± 2.23
299.6 99.87 ± 0.39
Average 102.27 ± 2.29
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A novel simple and sensitive fluorimetric method for the
determination of LND in bulk form and capsules has
been successfully developed and validated. The method
involved simple derivatization of LND with FLC reagent,
and subsequent measurement of the fluorescence inten-
sity of the fluorescent reaction product. The proposed
method is specific, accurate, reproducible, and highly
sensitive to be applied on the analysis of bulk form and
capsules. Furthermore, the analysis requires a simple
apparatus, thus the proposed method is suitable for rou-
tine analysis of LND in quality control laboratories.
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